Alzheimer disease (AD) is characterized by progressive cognitive decline in older
individuals accompanied by the presence of two pathological protein aggregates—amyloid …

The growing interest in nanomedicine over the last 20 years has carved out a research field
called “nanocatalytic therapy,” where catalytic reactions mediated by nanomaterials are …

Annotating the molecular basis of human disease remains an unsolved challenge, as 93%
of disease loci are non-coding and gene-regulatory annotations are highly incomplete …

Alzheimer's disease (AD) is a neurodegenerative disease associated with human aging.
Ten percent of individuals over 65 years have AD and its prevalence continues to rise with …

Abstract Background N6-methyladenosine (m 6 A) modification is known to impact many
aspects of RNA metabolism, including mRNA stability and translation, and is highly …

Complex diseases are characterized by spatiotemporal cellular and molecular changes that
may be difficult to comprehensively capture. However, understanding the spatiotemporal …

Mitochondrial dysfunction is a fundamental pathological feature of Alzheimer's disease (AD).
However, toxicity and poor brain enrichment of existing mitophagy inducers limit their further …

Background Synapse damage and loss are fundamental to the pathophysiology of
Alzheimer's disease (AD) and lead to reduced cognitive function. The goal of this review is to …

Alzheimer's disease (AD) is the most common type of senile dementia, characterized by
neurofibrillary tangle and amyloid plaque in brain pathology. Major efforts in AD drug were …

A key knowledge gap blocking development of effective therapeutics for Alzheimer's disease
(AD) is the lack of understanding of how amyloid beta (Aβ) peptide and pathological forms of …